PubMed HealthSearch

PubMed · 6131122

Rapid decrease in rat brain beta adrenergic receptor binding during combined antidepressant alpha-2 antagonist treatment.

Abstract

The delay in onset of the therapeutic effect of antidepressants is believed to be due to a progressive decrease in the density of central beta adrenergic receptors. The changes in beta adrenergic receptor density could result from an increase in the synaptic concentration of norepinephrine, which is secondary to a decrease in the sensitivity of the alpha-2 adrenergic receptor which normally inhibits release and the firing of the locus ceruleus. We have observed an acceleration of beta receptor desensitization with combined administration of antidepressants and alpha-2 adrenergic antagonists. After one day of administration of desipramine (DMI) with phenoxybenzamine, there was a marked decrease in beta adrenergic receptor density. One day of treatment with DMI alone had no significant effect on beta receptor density. Rapid desensitization occurs not only in rat limbic cortex, but also in hippocampus and mesencephalon. Furthermore, combination therapy of DMI with yohimbine or dihydroergotamine, both alpha-2 adrenergic blockers, is similar to DMI-phenoxybenzamine treatment. Combined administration with prazosin, an alpha-1 antagonist, had no effect on antidepressant-induced desensitization. Combined administration of alpha-2 antagonists accelerated beta receptor desensitization by amitriptyline, mianserin, iprindole, tranylcypromine and pargyline. These observations suggest that pharmacological blockade of alpha-2 adrenergic receptors enhances antidepressant-induced decreases in central nervous system beta-adrenergic receptor density.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J A Scott, F T Crews. 1983. Rapid decrease in rat brain beta adrenergic receptor binding during combined antidepressant alpha-2 antagonist treatment.. https://pubmed.ncbi.nlm.nih.gov/6131122/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of (+)-niguldipine on myocardial alpha 1-adrenoceptors in the rabbit.

The influence of the alpha 1A-adrenoceptor subtype-selective antagonist (+)-niguldipine on the alpha 1-mediated positive inotropic effect was assessed in the isolated rabbit ventricular myocardium. (+)-Niguldipine displaced the specific binding of [3H]prazosin to a membrane fraction derived from rabbit ventricular muscle with high (Ki = 64.6 pmol/l; RH = 23%) and low (Ki = 7.08 nmol/l) affinity. (+)-Niguldipine displaced specific [3H]CGP-121177 binding only at very high concentrations (Ki = 118 nmol/l). (+)-Niguldipine at 0.1 pmol/l and higher shifted the concentration-response curve for the alpha 1-mediated positive inotropic effect downwards, but at higher concentrations (up to 10 and 100 nmol/l) it did not cause a further shift of the curve. (+)-Niguldipine (1-100 nmol/l) did not affect the beta-mediated positive inotropic effect and the basal force of concentration. (-)-Niguldipine also showed a selective inhibitory action on the alpha 1-adrenoceptor-mediated positive inotropic effect, but its affinity and potency were approximately 1-2 log units lower than those of (+)-niguldipine. The present results indicate that the alpha 1A-adrenoceptor subtype is involved in the alpha 1-mediated positive inotropic effect. (+)-Niguldipine (or (-)-niguldipine with lower affinity) is able to antagonize selectively the cardiac alpha 1A-adrenoceptor-mediated positive inotropic effect. The magnitude of the alpha 1A-mediated inotropic effect, however, may be much less than that mediated by the alpha 1B-subtype in the rabbit ventricular myocardium.

Adrenergic alpha-Antagonists

Uptake of radioligands by rat heart and lung in vivo: CGP 12177 does and CGP 26505 does not reflect binding to beta-adrenoceptors.

The biodistribution of (-)-4-(3-t-butylamino-2-hydroxypropoxy)-[5,7-3H-benzimidazol-2-one (CGP12177, a non-selective beta-adrenoceptor antagonist) and 1-[2-(3-carbamoyl-4-hydroxy)-(5-3H-phenoxy)]-2-propanol methanesulfonate, (CGP26505, a beta 1-adrenoceptor antagonist) was studied in rats pretreated with various alpha- and beta-adrenoceptor blocking drugs (5 min before 3H injection, in dosages at which the drugs demonstrated the expected selectivity). Cardiac and pulmonary radioactivity were measured after 10 min, when specific binding was maximal. Uptake of [3H]CGP12177 was linked to binding to beta-adrenoceptors since it was not affected by prazosin or yohimbine, and was equally well inhibited by propranolol, unlabelled CGP12177 and isoprenaline. Moreover, atenolol and CGP20712A inhibited [3H]CGP12177 uptake in heart (predominantly beta 1-adrenoceptors) more potently than ICI 118,551, while in lungs (predominantly beta 2-adrenoceptors) ICI 118,551 was more potent than atenolol or CGP20712A. In contrast, [3H]CGP26505 uptake in the target organs was equally effectively inhibited by propranolol and ICI 118,551, and significantly lowered by alpha-adrenoceptor antagonists. We conclude that [11C]CGP12177, but not [11C]CGP2605 will be suitable for positron emission tomography imaging of beta-adrenoceptors in animals.

Adrenergic alpha-Antagonists